longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

159316

159316
----

LongbridgeAI

Ganfeng Lithium's Massive Earnings Rebound, and Plover Bay's Starlink Boost

Global Report
Sep 8, 2026 at 10:19 AM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

Ganfeng Lithium bounced back to profitability in the first half of 2026, while Plover Bay saw its Starlink partnership drive massive router demand. We also track major moves from Mengniu Dairy, CMS, and BeiGene.

Welcome to this sector roundup. The overarching theme for the first half of 2026 has been a significant rebound in corporate earnings, especially in the materials and tech infrastructure sectors.

The standout story is undoubtedly Ganfeng Lithium (1772.HK). The battery materials giant saw its revenue surge to RMB 22.88 billion in the first six months of 2026, bouncing back to a solid profit. This was a crucial turnaround, arriving just as China implemented a new 2% consumption tax on lithium-ion batteries starting in September.

Meanwhile, in the connectivity hardware space, Plover Bay Technologies (1523.HK) has been heavily riding the Starlink wave. As an authorized Starlink technology provider, its SD-WAN routers are experiencing a massive demand boost, pushing its mid-2026 revenue up over 18%. The company is now actively eyeing a Nasdaq spinoff for its North American business.

On the consumer and healthcare fronts, the big players are holding their ground. Mengniu Dairy (2319.HK) reported robust sales topping RMB 44.7 billion for the half-year, maintaining its dominance in premium milk. In the pharmaceutical sector, the company formerly known as BeiGene has rebranded its global identity to BeOne Medicines AG, though it continues its market operations as BeiGene (6160.HK). Another major healthcare player, CMS (1952.HK), saw its H1 2026 revenue jump a staggering 157% alongside key regulatory approvals for its cardiovascular medications.

Also in the pipeline:

  • Value Gold ETF (3081.HK) has been gaining serious traction, with its AUM hitting HKD 4.3 billion by September 2026, partly driven by insider talks that Hong Kong may ease MPF investment rules for gold ETFs.
  • Zhaojin Mining (1818.HK) continues to see robust momentum heading into its late-2026 reporting cycles, benefiting from broader strength in the precious metals ecosystem.
  • China XLX Fertiliser (1866.HK) recently distributed its mid-year dividend of HKD 0.37 per share, demonstrating consistent returns for shareholders.
  • JL MAG Rare-Earth (6680.HK) is quietly expanding its footprint in magnetic materials crucial for EVs and the emerging robotics sector.
  • ARTA TechFin (1421.HK) is navigating ongoing shifts in its electrical distribution and solar engineering segments as it continues to restructure its operations.

Login to unlock1,793characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Related Stocks

PLOVER BAY TECH

PLOVER BAY TECH

HK01523

0.00%

GANFENGLITHIUM

GANFENGLITHIUM

HK01772

-3.40%

EVEREST MED

EVEREST MED

HK01952

-6.09%